VYKOURA
Details
- Status
- Prescription
- First Approved
- 2026-02-03
- Routes
- INTRAMUSCULAR, INTRAVENOUS
- Dosage Forms
- SOLUTION
VYKOURA Approval History
What VYKOURA Treats
5 indicationsVYKOURA is approved for 5 conditions since its original approval in 2026. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Methotrexate Toxicity
- Folic Acid Antagonist Toxicity
- Dihydrofolate Reductase Inhibitor Toxicity
- Megaloblastic Anemia
- Metastatic Colorectal Cancer
Drugs Similar to VYKOURA
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VYKOURA FDA Label Details
ProIndications & Usage
FDA Label (PDF)VYKOURA is indicated for: 1.1 Rescue after high-dose methotrexate (MTX) therapy in adult and pediatric patients. 1.2 Reducing the toxicity of: Methotrexate in adult and pediatric patients with impaired methotrexate elimination or Folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult and pediatric patients. 1.3 Treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients when oral therapy is not feasible. 1.4 Treatment of patients with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.